Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT63XRS)

DTT Name	GDNF receptor alpha-3 (GFRA3)
Synonyms	UNQ339/PRO538/PRO3664; GFR-alpha-3; GDNFR-alpha-3; GDNF family receptor alpha-3
Gene Name	GFRA3
DTT Type	Clinical trial target	[1]
UniProt ID	GFRA3_HUMAN
TTD ID	T92042
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MVRPLNPRPLPPVVLMLLLLLPPSPLPLAAGDPLPTESRLMNSCLQARRKCQADPTCSAA YHHLDSCTSSISTPLPSEEPSVPADCLEAAQQLRNSSLIGCMCHRRMKNQVACLDIYWTV HRARSLGNYELDVSPYEDTVTSKPWKMNLSKLNMLKPDSDLCLKFAMLCTLNDKCDRLRK AYGEACSGPHCQRHVCLRQLLTFFEKAAEPHAQGLLLCPCAPNDRGCGERRRNTIAPNCA LPPVAPNCLELRRLCFSDPLCRSRLVDFQTHCHPMDILGTCATEQSRCLRAYLGLIGTAM TPNFVSNVNTSVALSCTCRGSGNLQEECEMLEGFFSHNPCLTEAIAAKMRFHSQLFSQDW PHPTFAVMAHQNENPAVRPQPWVPSLFSCTLPLILLLSLW
Function	Mediates the artemin-induced autophosphorylation and activation of the RET receptor tyrosine kinase. Receptor for the glial cell line-derived neurotrophic factor, ARTN (artemin).
Reactome Pathway	RET signaling (R-HSA-8853659 ) RAF/MAP kinase cascade (R-HSA-5673001 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Neublastin	DMOZW4C	Pain	MG30-MG3Z	Phase 2	[1]
------------------------------------------------------------------------------------

References

1	First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica. PLoSOne. 2015 May 11;10(5):e0125034.